Pyronaridine - Collaborations Pharmaceuticals/University of California/University of Sao Paulo
Latest Information Update: 28 Feb 2024
At a glance
- Originator Collaborations Pharmaceuticals; University of California, San Diego; University of Sao Paulo
- Class Acridines; Antimalarials; Antineoplastics; Chlorinated hydrocarbons; Naphthyridines; Pyrrolidines; Small molecules
- Mechanism of Action Hemozoin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections; Ebola virus infections; Malaria
- No development reported Chagas disease
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Chagas-disease in Brazil
- 28 Feb 2024 No recent reports of development identified for preclinical development in Chagas-disease in USA
- 09 Feb 2022 Collaborations Pharmaceuticals intends to initiate clinical trial in COVID-2019 infections in South Korea (Collaborations Pharmaceuticals pipeline, February 2022)